Developing CAR-T cell technology platform for cancer immunotherapyTctd@1232021-12-31T07:03:20+00:00
Developing CAR-T cell technology platform for cancer immunotherapy
PI: Prof. Rahul Purwar, Department of Biosciences and Bioengineering
B cell-Acute Lymphocytic Leukemia (B-ALL) is a form of haemotological malignancy or leukemia, which is most common in childhood. Haematological malignancies are malignant neoplasms (cancer) that are treated by haematologists and oncologists. Cancer starts when cells in the body begin to grow out of control. Recently, Chimeric Antigen Receptor (CAR) T-cell therapy has shown remarkable results in treating haematological malignancy especially B-ALL. Currently, the overall survival (OS) of pediatric B-Acute Lymphoblastic Leukemia in India is around 70 per cent. However, 20-25 per cent Acute Lymphoblastic Leukemia patients relapse making it on par with Soft Tissue Sarcomas as the fourth commonest pediatric malignancy. The project is aimed at developing the CAR-T cell platform; CAR-T cells work very effectively in treating relapse and refractory to B-ALL patients.